ITRI-501 exhibits the strongest ADCC activity than the benchmark antibodies. In human TIGIT gene knock-in mouse syngeneic model, ITRI-501 alone is highly potent in inhibiting MC38 tumor cell growth. Cell line development and lab-scale process and formulation have been completed with manufacturability.
Applications:Cancer Immunotherapy, single or combination therapies.